The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed.
The purpose of this study is to review the impact of generic bisphosphonates on effectiveness in the treatment of osteoporosis.
This study is a literature review.
A substantial body of evidence indicates that many generic formulations of alendronate are more poorly tolerated than the proprietary preparations which results in significantly poorer adherence and thus effectiveness. Poorer effectiveness may result from faster disintegration times of many generics that increase the likelihood of adherence of particulate matter to the oesophageal mucosa. Unfortunately, market authorisation, based on the bioequivalence of generics with a proprietary formulation, does not take into account the potential concerns about safety. The poor adherence of many generic products has implications for guideline development, cost-effectiveness and impact of treatment on the burden of disease.
The impact of generic bisphosphonates requires formal testing to re-evaluate their role in the management of osteoporosis.
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.PG. JAMA 282:11344–11352 CrossRef
Agence Française de Sécurité Sanitaire des Produits de Santé (2006) 19/01/2006 - Traitement médicamenteux de l’ostéoporose post-ménopausique - recommandations de bonne pratique. http://www.afssaps.fr/content/search?SearchText=osteoporose&ok=Valider
Pfeilschifter J (2006) 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 114:611–622 PubMed
Adami S, Bertoldo F, Brandi ML et al (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284 PubMed
Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, London
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428 PubMedCrossRef
Kanis J, McCloskey E, Jönsson B, Cooper A, Ström O, Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48 CrossRef
Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London
National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London, NICE. November 2010
González M, Guañabens GN, Gómez C et al (2008) (Comité de Redacción, en representación del Comité de Expertos de la SEIOMM para la elaboración de las Guías). Practice guidelines for postmenopausal, steroid-induced and male osteoporosis. Spanish Society for Bone and Mineral Research. Rev Clin Esp 208(suppl 1):1–24
Figueras J, McKee M, Lessof S et al (2008) Health systems, health and wealth: assessing the case for investing in health systems. World Health Organization 2008 and World Health Organization, on behalf of the European Observatory on Health Systems and Policies. Available at: http://www.euro.who.int. Accessed 7 May 2011
Johnston A (2010) Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. CMRO 26:871–878 CrossRef
Hakonsen HH, Eilertsen M, Borge H, Toverud EL (2009) Generic substitution: additional challenge for adherence in hypertensive patients? CMRO 25:2515–2521 CrossRef
EMEA (1998) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev.1. Available at: http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm. Accessed 7 May 2011
Kane S, Borisov N, Brixner D (2004) Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care 10:S216–S228
Perkins AC, Blackshaw DE, Hay PD et al (2008) Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 30:834–844 PubMedCrossRef
Halkin H, Dushenat M, Silverman B (2007) Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 41:29–34 PubMed
Olszynski WP, Adachi J, Davison J, Davison KS (2010) Disintegration times of brand and generic bisphosphonates available in Canada. J Bone Miner Res 25:S125
Almeida S, Almeida A, Filipe A et al (2006) In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. Arzneimittelforschung 56:84–89 PubMed
Epstein S, Geusens P, Fisher JE et al (2005) Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Applied Res 5:253–264
Department of Heath and Ageing (2011) Australian public assessment report for alendronic acid. Australian Government, Department of Health and Ageing Therapeutics Goods Administration. Submission PM-01135-3-5, February 2011
Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 286:202–210 CrossRef
- A reappraisal of generic bisphosphonates in osteoporosis
J. A. Kanis
J. D. Adachi
Neu im Fachgebiet Orthopädie und Unfallchirurgie
e.Med Kampagnen-Visual, Mail Icon II